Boletín de AInvest
Titulares diarios de acciones y criptomonedas, gratis en tu bandeja de entrada
Altria Group's stock has surged 10% in the past week and 6% YTD, outperforming the broader market. The FDA's approval of its on! Plus nicotine pouches could enhance its product offerings. Despite mixed analyst ratings, the stock's attractive dividend yield continues to draw income-focused investors. Analysts are divided, with five rating MO as a Buy, eight as Hold, and two as Sell.
Titulares diarios de acciones y criptomonedas, gratis en tu bandeja de entrada
Comentarios
Aún no hay comentarios